Regenta Duo Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
MFDS item code 202400611 · Approved 2024.03.22
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is prescribed to help manage blood sugar levels in patients with type 2 diabetes who are taking both linagliptin and metformin. When used in conjunction with dietary and exercise regimens, it allows for more effective management of blood sugar levels. This contributes to improving the patients' blood sugar levels and preventing diabetes-related complications.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.
This medication helps in controlling blood sugar levels. However, it may rarely cause a serious condition known as lactic acidosis, so caution is needed. It is particularly unsafe for patients with poor renal function, liver problems, or those who have had an acute myocardial infarction or heart failure. Additionally, it should not be administered to individuals with acute alcohol intoxication or alcohol dependence. Because of the risk of hypoglycemia, careful observation of blood sugar changes is necessary when used in conjunction with other hypoglycemic agents such as insulin or sulfonylureas. Since this medication can be affected by kidney function, regular kidney function tests should be carried out, and the medication may need to be discontinued if kidney function decreases. When receiving iodine contrast agents used in radiological examinations, this medication should be temporarily discontinued before and after the examination. It is also necessary to stop taking this medication for a period before undergoing surgery. During treatment, side effects such as acute pancreatitis or skin blisters similar to pemphigus may occur; if these symptoms arise, you must immediately inform your physician. This medication can cause vitamin B12 deficiency, so checking vitamin B12 levels is advisable for long-term users. Do not chew or crush the tablets; swallow them whole, and it is normal for the tablet shell to appear in the stool. It is recommended to avoid using this medication during pregnancy or breastfeeding, and consult a physician if planning to become pregnant. Safety and efficacy in children have not been established, and elderly patients may require dose adjustments and regular kidney function testing due to possible renal impairment. In overdose situations, there is a risk of lactic acidosis, and immediate medical attention should be sought. Keep this medication out of the reach of children, avoid moisture, and do not transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should maintain room temperature between 1 and 30 degrees Celsius. This will help safely maintain the drug's effectiveness.
Oval sustained release tablet, white to almost white, inscribed with SJ251 on one side
28 tablets/box (7 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.